RNA Supply Chain Resources

1. CRISPR sgRNA For Successful Gene Editing: Discovery To Clinic 9/25/2023

   The single guide RNA (sgRNA) is one of the key components of successful CRISPR gene editing. Here we cover all the important aspects of sgRNA and Synthego’s sgRNA products.

2. Moderna's Regulatory Journey: 3 Takeaways To Foster The mRNA Renaissance 1/2/2024

   The story of how Moderna brought one of the first mRNA vaccines to the market has all the makings of a legend we will pass down through generations. However, unlike the legends of King Arthur or The Fountain of Youth, we can celebrate that Moderna’s legendary journey was — and still is — real. Not only did the mRNA vaccines help return life to normal, but they also kickstarted the mRNA therapeutic renaissance we’re happily experiencing today.

3. The Role Of CRISPR Cas9 Plasmids In Gene-Editing 12/12/2023

   Plasmids are crucial for CRISPR-Cas9 gene-editing technology, and their role in CRISPR is expected to evolve with ongoing research.

4. Where Can Novel Non-Viral Polymeric Delivery Agents Take Us? 1/18/2023

   Explore ongoing work to harness different types of HDR templates in order to build cutting-edge systems with the potential to enable point-of-care cell and gene therapy manufacture.

5. Review Of mRNA Vaccines & Therapeutics Manufacturing Challenges: Plasmid DNA Manufacturing 6/7/2022

   This review suggests technical remedial options for the production of pDNA and focuses on mRNA synthesis, purification, and encapsulation.

6. Novel Lipid Nanoparticle Delivery Reagent And Manufacturing Workflow 4/18/2022

   We aim to highlight that commercially available LNP reagent mix, GenVoy-ILM, is an accessible and easy-to-use LNP formulation that allows for rapid preclinical development of RNA vaccines.

7. Mastering mRNA Manufacturing: A Focus on Raw Materials & Supply Assurance 10/23/2024

   Rapid advancements in mRNA-based therapeutic development have underscored the role of raw material quality and supply chain management in ensuring their successful production.

8. Gene And Cell Therapy: Planning For Manufacturing Success Early 1/16/2023

   As gene therapy organizations are asked to balance the need for rapid clinical progression and stringent quality expectations, explore how to optimize plasmid production and reach patients with efficiency.

9. Reduce Contamination Risks When Storing Synthetic DNA 10/30/2023

   An alternative to traditional polyethylene bags is offering cell and gene therapy manufacturers a solution to contamination concerns regarding DNA or RNA fragments.

10. GMP-Source® And Phase-Appropriate Use For Early-Stage Clinical Trials 9/16/2021

    GMP-Source is a more robust, less rigid alternative to full cGMP production that mirrors nearly all of the oversight and quality standards of full cGMP production while relaxing certain commercial standards, helping companies overcome the hurdles that can stall early development.